FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Removed claim: co-financing rate (P837): 49.9999986592314 percent) |
||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 49.9999986592314 percent / rank | |||||||
Revision as of 04:32, 20 March 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES |
Project in Italy financed by DG Regio |
Statements
186,460.21 Euro
0 references
372,920.43 Euro
0 references
14 February 2017
0 references
13 October 2019
0 references
EVVIVAX S.R.L.
0 references
ISTITUTO SUPERIORE DI SANITA'
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà , LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
0 references
Identifiers
F89J18000160007
0 references